An Open Label Multicentre Single Arm Study to Characterise the Efficacy Safety and Tolerability of Gefitinib 250 mg IRESSA as First line Treatment in Caucasian Patients who have Epidermal Growth Factor Receptor EGFR Mutation Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer NSCLC